1. Scrip
  2. >>Focus On Asia
  3. >>China

Rare Opening In Tough Times: New Biotechs Rekindle CNS Development In China

But Regulatory Barriers Remain

 
• By Brian Yang

A slew of high-level executives has established biotech startups in China with a single focus on CNS conditions. Emerging collaboration and funding flow highlights a heating up market, but insiders tell Scrip that choppy waters and an uncertain future may be looming.

nerve cells, concept for neurodegenerative and neurological disease
Chinese biotechs flock to CNS development but funding, regulatory worries remain • Source: Shutterstock

After leading a Nasdaq-listed Chinese biotech, I-Mab Biopharma Co., Ltd, as CEO for years, Joan Shen has started and is CEO of her own new bioventure, NeuShen Therapeutics, which is focusing on central nervous system conditions.

The first target disorder for the Shanghai- and Lexington-based startup is amyotrophic lateral sclerosis (ALS), a rare and rapid progressive neurodegenerative condition

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.

CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

 
• By Xu Hu

CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.